Abstract
Background: Multidrug resistance in cancer is the ability of a cancer cell to resist treatment with a wide range of structurally and functionally dissimilar chemotherapeutics. The resistant phenotype could arise in response to several cellular changes that ultimately result in a decrease in intracellular drug accumulation (or effectiveness), either by limiting cellular drug entry, or by expulsion of those molecules that have made it into the cell. Both blocking drug cellular entry and its expulsion are mostly brought about by the cell membrane. Several pharmaceutical excipients (mainly lipids, surfactants and amphililc copolymers) have been reported to reverse multidrug resistance by addressing cell membrane related changes resulting in low intracellular drug levels in resistant cells. These excipients are routinely used in the preparation of lipid based nanoparticles endowing inherent multidrug resistance reversing properties to these nanoparticles.
Methods: In this review, cell membrane alterations resulting in multidrug resistance will be initially reviewed, followed by a discussion of the different types of lipid NPs and the potential held by the excipients used in their preparation in multidrug resistance reversal. Finally, a discussion on how lipid nanoparticles have been engineered and used in different occasions to enable multidrug resistance reversal is included.
Conclusion: The superior role held by lipid nanoparticles in comparison to free excipients will be highlighted.
Keywords: MDR Cancer, liposomes, lipid nanocapsules, solid lipid nanoparticles, nanostructured lipid carriers, multidrug resistance.
Current Pharmaceutical Design
Title:Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Volume: 23 Issue: 43
Author(s): Salma N. Tammam*
Affiliation:
- Pharmaceutical Technology Department, the German University in Cairo (GUC), Cairo,Egypt
Keywords: MDR Cancer, liposomes, lipid nanocapsules, solid lipid nanoparticles, nanostructured lipid carriers, multidrug resistance.
Abstract: Background: Multidrug resistance in cancer is the ability of a cancer cell to resist treatment with a wide range of structurally and functionally dissimilar chemotherapeutics. The resistant phenotype could arise in response to several cellular changes that ultimately result in a decrease in intracellular drug accumulation (or effectiveness), either by limiting cellular drug entry, or by expulsion of those molecules that have made it into the cell. Both blocking drug cellular entry and its expulsion are mostly brought about by the cell membrane. Several pharmaceutical excipients (mainly lipids, surfactants and amphililc copolymers) have been reported to reverse multidrug resistance by addressing cell membrane related changes resulting in low intracellular drug levels in resistant cells. These excipients are routinely used in the preparation of lipid based nanoparticles endowing inherent multidrug resistance reversing properties to these nanoparticles.
Methods: In this review, cell membrane alterations resulting in multidrug resistance will be initially reviewed, followed by a discussion of the different types of lipid NPs and the potential held by the excipients used in their preparation in multidrug resistance reversal. Finally, a discussion on how lipid nanoparticles have been engineered and used in different occasions to enable multidrug resistance reversal is included.
Conclusion: The superior role held by lipid nanoparticles in comparison to free excipients will be highlighted.
Export Options
About this article
Cite this article as:
Tammam N. Salma *, Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer, Current Pharmaceutical Design 2017; 23 (43) . https://dx.doi.org/10.2174/1381612823666171122104738
DOI https://dx.doi.org/10.2174/1381612823666171122104738 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Synthesis of New Thiazolyl-Pyrazoline Derivatives and Evaluation of Their Antimicrobial, Cytotoxic and Genotoxic Effects
Letters in Drug Design & Discovery The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Therapeutic Potential of Herbal Molecules against Breast Cancer
Current Nutrition & Food Science Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Current Cancer Drug Targets Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design